thiazoles has been researched along with Cutaneous T-Cell Lymphoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andersen, MH; Berthelsen, J; Bonefeld, CM; Francavilla, C; Fredholm, S; Geisler, C; Hu, T; Krejsgaard, T; Odum, N; Olsen, JV; Petersen, DL; Sibbesen, NA; Wasik, MA; Willerslev-Olsen, A; Woetmann, A; Zhang, M | 1 |
| Krett, NL; Rosen, ST; Rovedo, MA | 1 |
2 other study(ies) available for thiazoles and Cutaneous T-Cell Lymphoma
| Article | Year |
|---|---|
B-lymphoid tyrosine kinase (Blk) is an oncogene and a potential target for therapy with dasatinib in cutaneous T-cell lymphoma (CTCL).
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Dasatinib; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, T-Cell, Cutaneous; Mice; Neoplasm Transplantation; Neoplasms; Phosphorylation; Pyrimidines; src-Family Kinases; Thiazoles | 2014 |
Inhibition of glycogen synthase kinase-3 increases the cytotoxicity of enzastaurin.
Topics: Antineoplastic Agents; beta Catenin; Cells, Cultured; Glycogen Synthase Kinase 3; Humans; Hyaluronan Receptors; Indoles; Lymphoma, T-Cell, Cutaneous; Protein Kinase C; Protein Kinase Inhibitors; Skin Neoplasms; TCF Transcription Factors; Thiazoles; Urea | 2011 |